Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase 3 SENTRY Trial (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-752; Location: LEVEL 3, HALL B3; P3 | "Selinexor plus ruxolitinib significantly improved SVR35, with comparable symptom improvement to ruxolitinib and manageable safety. Promising OS was observed and SVR35 responses predicted OS. These results establish selinexor plus ruxolitinib as a potential frontline option in myelofibrosis."
P3 data • Myelofibrosis • Oncology
|
|
John Mascarenhas 1; Haris Ali 2; Haifa Al-Ali 3; Jose Valentin Garcia Gutierrez 4; Sebastian Grosicki 5; Zhanet Grudeva-Popova 6; Claire Harrison 7; Junshik Hong 8; Hsin-An Hou 9; Michal Kwiatek 10; Michael Loschi 11; Francesco Passamonti 12,13; Andrea Patriarca 14; Nikolai Podoltsev 15; Raajit Rampal 16; Srinivas Tantravahi 17; Laura Gabriela Urian 18; Reshma Rangwala 19; Pankit Vachhani 20; Prithviraj Bose 21
|